Avian influenza is an infection caused by avian (bird) influenza (flu) viruses. These influenza viruses occur naturally among birds. Wild birds worldwide carry the viruses in their intestines, but usually do not get sick from them. However, avian influenza is very contagious among birds and can make some domesticated birds, including chickens, ducks, and turkeys, very sick and kill them.
Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.
A compact, self-contained, automated system for surveillance and screening of potential pandemic strains of influenza and other deadly infectious diseases is a step closer to reality, thanks to an agreement between Los Alamos National Laboratory, the University of California Los Angeles School of Public Health, and HighRes Biosolutions of Boston, Massachussets.
After six birds were confirmed to have avian flu, the Miyazaki Prefectural Government has begun culling more than 10,000 chickens at a local poultry farm southwest Japan.
Influenza from birds, commonly known as H5N1 avian flu, has killed at least 306 people during the past seven years and innumerable birds and poultry. Now a team of scientists in Britain have developed a way to breed poultry that are genetically resistant to H5N1 or any other avian flu virus. The study by Scientists from Cambridge and Edinburgh universities was reported in the Jan. 13 issue of Science.
Medicago, a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine.
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.
Habitat destruction and species extinction may lead to an increase in diseases that infect humans and other species, according to a paper in the journal Nature co-authored by a University of Florida ecologist.
Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.
Two new tools that enable the public to report sick or dead wild animals could also lead to the detection and containment of wildlife disease outbreaks that may pose a health risk to people.
A study published in the Journal of Infectious Diseases indicates that treatment with oseltamivir significantly reduces mortality in patients with influenza A/H5N1, or 'bird flu', even when given late in the course of illness.
On the eve of the 2010-11 influenza flu season, scientists and engineers have identified the environmental conditions and surfaces that could enable a highly pathogenic (H5N1) bird flu virus to survive for prolonged periods of time at least two weeks and up to two months. Among them: The virus appears to thrive at cooler temperatures and low humidity.
Johns Hopkins has a wide range of experts available for interviews and comments about seasonal flu, H1N1, emergency preparedness, infection control, flu transmission in children, vaccine safety, flu treatment, public health ethics, flu in cancer patients, and related public communications strategies. If you would like to interview a Johns Hopkins expert, call or e-mail the designated information officer in the list below.
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer, and chronic infectious disease applications of the Aethlon Hemopurifier®.
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.
CytoGenix, Inc. today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.
CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus.
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.
Consumer demand for safe eggs has driven retail sales of pasteurized shell eggs up by more than 50% since Aug. 16 when the Food and Drug Administration (FDA) recommended their use to prevent illness from egg-related Salmonella Enteritidis, announced National Pasteurized Eggs (NPE).
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."
A new compound may offer an effective drug candidate against the deadly tropical infection, Chagas' disease say researchers from Brazil. They report their findings in the August 2010 issue of the journal Antimicrobial Agents and Chemotherapy.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.